Cardiology

Top Medical News
Healthy eating may prevent heart failure in men
2 hours ago
Adherence to a healthy diet can help reduce the risk of heart failure (HF) with reduced ejection fraction (HFrEF), as seen in both the Alternative Healthy Eating Index (AHEI) and the clinically abbreviated Prime Diet Quality Score (PDQS), reveals a study.
Time in SBP target range predicts adverse event risk in NVAF
5 hours ago
The time in target rage (TTR) of systolic blood pressure (SBP) appears to be predictive in assessing the risk of cardiovascular death in patients with nonvalvular atrial fibrillation (NVAF), reports a recent study.
Canagliflozin improves HF symptoms, QoL regardless of diabetes status
23 hours ago
Treatment with the sodium‐glucose cotransporter 2 inhibitor canagliflozin protects against cardiovascular events in patients with comorbid type 2 diabetes (T2D) and chronic kidney disease (CKD), with a larger absolute benefit for total cardiovascular than first cardiovascular events, according to a post hoc analysis.
OSA tied to coronary collateral vessel development in STEMI patients
Yesterday
Patients with ST-segment elevation myocardial infarction (STEMI) are more likely to develop a coronary collateral vessel (CCV) in the presence of obstructive sleep apnoea (OSA), according to a study.
Low DASH score ups CVD mortality risk in adults with genetic predisposition to smoking
Stephen Padilla, Yesterday
Adults with a genetic susceptibility to smoking are at increased risk of dying due to a cardiovascular disease (CVD), suggest the results of the Singapore Chinese Health Study.
Coagulation abnormalities compromise COVID-19 survival
Yesterday
Patients with abnormalities in coagulation parameters such as prothrombin concentration (PC) and D-dimer (DD) levels are at greater risk of more severe COVID-19 infection and subsequent death, reports a recent study.
Cardiac damage extent, change at 1 year help predict post-AVR outcomes
2 days ago
The extent of extravalvular cardiac damage at baseline and its change at 1 year provide significant prognostic implications in patients undergoing aortic valve replacement (AVR), suggests a study.
Special Reports
Empagliflozin: A new dawn for heart failure treatment across the ejection fraction spectrum
06 Jun 2022

Initially approved to improve glycaemic control and reduce cardiovascular death in adults with type 2 diabetes (T2D), the SGLT-2* inhibitor empagliflozin reduced hospitalization for heart failure (HFH) or cardiovascular death and delayed renal function decline when added to recommended therapy in patients with heart failure and reduced ejection fraction (HFrEF) in the EMPEROR-Reduced** trial. The EMPEROR-Preserved** trial has now shown that the benefits of empagliflozin extend to patients with heart failure and preserved ejection fraction (HFpEF).

Early and consistent: Breakthrough results in HFpEF similar to HFrEF
14 Jan 2022
HFpEF represents a significant unmet need in CV medicine due to its prevalence, poor prognosis, and the absence of clinically proven therapeutic options. The EMPEROR-Preserved trial demonstrated the continuous clinical benefits in cardiorenal outcomes of empagliflozin in adults with HFpEF, which were consistent with the observations in adults with HFmrEF/ HFpEF in the EMPEROR-reduced trial. The combined results of the EMPEROR trials establish empagliflozin’s efficacy in heart failure regardless of ejection fraction – and if approved, empagliflozin would become the first and only clinically proven therapy to improve outcomes for the full spectrum of the disease. Therefore, empagliflozin offers a new hope for people living with heart failure.
EMPEROR-Preserved: The first successful trial to improve outcomes in HFpEF
18 Nov 2021
Heart failure with preserved ejection fraction (HFpEF) represents a significant unmet medical need. The EMPEROR-Preserved trial aimed to assess the impact of empagliflozin on cardiovascular outcomes in patients with HFpEF. On 27 August 2021, during the hotline session of the 2021 ESC Virtual Congress, the main results of the EMPEROR-Preserved trial were presented by Professor Stefan Anker, principal investigator of the study, and heart failure specialist at Charité Berlin, Germany.
NOACs in nonvalvular atrial fibrillation with multimorbidity: Where does apixaban stand?
02 Nov 2021
Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in clinical practice, affecting millions of people globally. Stroke is one of its devastating complications, with the risk steeply increasing with advancing age. Additionally, AF is associated with more than a tripling of the risk of systemic embolic (SE) events. [J Am Heart Assoc 2020;9:e016724]
Product Highlight - Lixiana
29 Sep 2021
Edoxaban 30 mg and 60 mg FC tab
Product Highlight - VIACORAM
16 Jun 2021
Perindopril arginine 3.5 mg,
Amlodipine besilate 2.5 mg tab
Trimetazidine new formulation redefining angina control in daily practice
12 Mar 2021
Chronic coronary syndrome (CCS) remains a leading cause of death and disability worldwide. The dual goals of CCS management is to prevent future cardiac events, such as myocardial infarction and death, and to reduce ischaemia and relieve angina symptoms, says Prof Peter Yan, consultant cardiologist and medical director, Peter Yan Cardiology Clinic, Gleneagles Medical Centre, Singapore, during a Servier-sponsored virtual symposium.
Conference Reports
Antithrombotics after a stroke: In whom, when and how?
Natalia Reoutova, 06 Jul 2022

Large well-designed studies published in recent years point to an association of cerebral microbleeds (CMBs) with increased risks of intracerebral haemorrhage (ICH) and ischaemic stroke (IS). Although the association of CMBs with ICH is greater than with IS, the absolute incidence of IS is still higher than of ICH, implying that antithrombotics should not be routinely withheld for all patients with CMBs.

Paclitaxel-coated devices in femoropopliteal artery revascularization
Roshini Claire Anthony, 10 Jun 2022

Among patients undergoing femoropopliteal artery revascularization, mortality risk was not affected regardless of whether they were treated with drug-coated devices (DCDs) or non–drug-coated devices (NDCDs), according to updated results of the SAFE-PAD* study presented at SCAI 2022.

Clopidogrel monotherapy trumps aspirin monotherapy in reducing CV events post-PCI
Roshini Claire Anthony, 03 Jun 2022

One year after undergoing percutaneous coronary intervention (PCI), high-risk patients on clopidogrel monotherapy have a reduced risk of multiple cardiovascular (CV) outcomes compared with those on aspirin monotherapy, according to a study presented at SCAI 2022.

IVL maintains superiority over PTA at 1 year for peripheral artery calcification
Audrey Abella, 03 Jun 2022
In the Disrupt PAD III trial, superior primary patency (PP) was achieved at 1 year with intravascular lithotripsy (IVL) plus a drug-coated balloon (DCB) compared with percutaneous transluminal angioplasty (PTA) + DCB, confirming the consistent safety and efficacy of IVL to facilitate a durable approach for individuals with heavily calcified femoropopliteal arteries largely without stent requirement.
Harmony TPV continues to show safety, efficacy for recipients at 1 year
Audrey Abella, 02 Jun 2022
In an expanded analysis presented at SCAI 2022, recipients of the Harmony transcatheter pulmonary valve (TPV) continued to demonstrate favourable clinical and haemodynamic outcomes, confirming previous results and showing continued device success across studies and valve types at 1 year and beyond.
Post-TAVR SLT does not differ with edoxaban or DAPT
Roshini Claire Anthony, 16 May 2022

The risk of subclinical valve leaflet thrombosis (SLT) following transcatheter aortic valve replacement (TAVR) did not differ regardless of whether patients received edoxaban or dual antiplatelet therapy (DAPT) post-surgery, according to results of the ADAPT-TAVR* trial.

New HF guideline:
Quad therapy, HFmrEF, and more
Elvira Manzano, 04 May 2022
Hot on the heels of ACC.22 ground-breaking reports, the ACC/AHA/HFSA* released the 2022 heart failure (HF) guideline, with special emphasis on quad therapy for patients with reduced ejection fraction.